Dear All, Two items for your attention today: an immediate action for you to take to support PASTEUR plus a launch event for a major Wellcome Trust project for your calendar. First, as you may recall, the Oversights & Investigations Subcommittee of the US House Energy & Commerce Committee recently held a hearing about the impact of AMR.
Dear All (Wonkish alert! Coffee-up!), Today we have something special: A deep-dive into the future trajectory of AMR-related work developed by Wellcome Trust. The newly released report is here and there is a webinar discussing the report on Wednesday of this week (1500-16:00 GMT on 18 Nov 2020, go here to register). The back story
Dear All, And now for something really different! With the recent GRAM report (20 Jan 2022 newsletter) showing that AMR is linked to more deaths that HIV or malaria (#AMRSOS! Andrew Jack and FT team have some great graphics for this … check them out!), we now have an absolutely fascinating call from Wellcome Trust for
Dear All, There are days when it is hard to keep up! Not only did we have the release today of two amazing sets of RFPs from NIAID and BARDA (Vaccines! Therapeutics! Diagnostics! Bacteria! Fungi! Viruses! See this newsletter!) but we also have the impressive GRAM (Global Research on Antimicrobial Resistance) report by Murray et
Dear All, Novel antibacterial agents, vaccines, and diagnostics will do little if they are not widely available and used responsibly. CDDEP’s recent report entitled “The State of the World’s Antibiotics in 2021” makes this very clear: “… more people in LMICs (low-middle-income countries) die from lack of access to antimicrobials than from resistant infection.” Hence, CARB-X has
Dear All, The Wellcome Trust Drug-Resistant Infections team wants to understand what researchers in academia and SMEs need to enable them to be better able to make progress with their early antibiotic discovery projects. Although some programs are now in place (e.g., the accelerator support provided by CARB-X), what are the remaining barriers? To help
Dear All: Greetings in the new year! Two things of general interest today: First, Wellcome Trust has posted an opening for a Science Officer to help develop and implement Wellcome’s work on Drug-Resistant Infections (a copy of job description is here). In this role, you would work closely within a very strong team to implement and support Wellcome’s diverse
Dear All, See below my signature: A 6-month consultancy with WHO to support the the SECURE initiative, a program to assist countries in accessing and sustainably managing new and existing antibiotics needed to cope with antimicrobial resistance (AMR). There’s not much online (yet) about SECURE: the best description I can find is in the Terms of Reference
Dear All: The international conversation continues apace following the recent DRIVE-AB meeting on antibiotic incentives. There are two further important meetings coming up that you may wish to know about. First, Wellcome Trust is co-hosting a side-event with the UN Foundation during the UN General Assembly on 21 Sep (yes, this week!). The side event is from 8a-10a in
Dear All: Wellcome Trust (WT) is seeking a Science Lead for WT’s Drug-Resistant Program (DRI) programme. This is a very senior role with global reach: the Science Lead reports to the Head of the DRI programme and has direct responsibility for leading the team that executes and monitors the DRI science strategy. The DRI program spans 4 pillars:
Using ideas to connect, create, and inspire
Supported by the Wellcome Trust